EFPIA welcomes IMI2 to boost industry investment in Europe

7 May 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the adoption of the second Innovate Medicines Initiative (IMI2) regulation by the European Council.

It is hoped that it will continue the success of the first IMI, a public-private partnership between the European Union and the EFPIA that aims to advance research and development, particularly in areas of unmet medical need. IMI2 will develop IMI’s vision of service to public health needs, having looked to the World Health Organization’s Report on Priority Medicines for Europe and the World in determining its Strategic Research Agenda (SRA). The SRA, an essential element of the evolution from IMI to IMI2, was determined with input from more than 80 organisations, including regulators, patients, academia and learned societies. The initial focus of IMI2 will be on fields such as neuro-degeneration, metabolic disorders, immune-mediated diseases, infections and translational safety.

Tangible outcomes for patients

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK